Total submissions: 17
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000482079 | SCV000344601 | pathogenic | not provided | 2016-09-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000482079 | SCV000565067 | pathogenic | not provided | 2020-04-02 | criteria provided, single submitter | clinical testing | Frameshift variant that results in nonsense mediated mRNA decay (Hazelwood et al., 1997) in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 29445374, 8896559, 9345105, 30055995, 20662851, 9562579, 31898847) |
Genetic Services Laboratory, |
RCV000005595 | SCV000595166 | pathogenic | Hermansky-Pudlak syndrome 1 | 2015-10-14 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000614559 | SCV000711718 | pathogenic | Hermansky-Pudlak syndrome | 2023-12-21 | criteria provided, single submitter | clinical testing | The p.His497GlnfsX90 variant in HPS1 has been reported in the homozygous or compound heterozygous state in >20 individuals with Hermansky-Pudlak syndrome and has been described as founder variant in Puerto Rican population (Oh 1996 PMID: 8896559, Carmona-Rivera 2010 PMID: 20662851). It has been identified in 0.02% (7/35412) of Latino/Admixed American chromosomes by gnomAD (http://gnomad.broadinstitute.org). This variant has also been reported in ClinVar (Variation ID 5277). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 497 and leads to a premature termination codon 90 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the HPS1 gene is an established disease mechanism in Hermansky-Pudlak syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Hermansky-Pudlak syndrome. ACMG/AMP Criteria applied: PVS1, PM3_VeryStrong. |
Clinical Molecular Genetics Laboratory, |
RCV000005595 | SCV000844947 | pathogenic | Hermansky-Pudlak syndrome 1 | 2018-10-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000482079 | SCV000959691 | pathogenic | not provided | 2025-01-21 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.His497Glnfs*90) in the HPS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HPS1 are known to be pathogenic (PMID: 12442288, 16185271). This variant is present in population databases (rs281865163, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with Hermansky-Pudlak syndrome (PMID: 8896559, 9562579, 20662851). It is commonly reported in individuals of Puerto Rican ancestry (PMID: 8896559, 9562579, 20662851). ClinVar contains an entry for this variant (Variation ID: 5277). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV001266458 | SCV001444633 | pathogenic | Inborn genetic diseases | 2018-04-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000005595 | SCV001752508 | pathogenic | Hermansky-Pudlak syndrome 1 | 2024-03-29 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000005595 | SCV002025013 | pathogenic | Hermansky-Pudlak syndrome 1 | 2019-09-28 | criteria provided, single submitter | clinical testing | |
Broad Center for Mendelian Genomics, |
RCV000614559 | SCV002097054 | pathogenic | Hermansky-Pudlak syndrome | 2021-11-29 | criteria provided, single submitter | curation | The p.His497fs variant in HPS1 has been reported in more than 10 individuals with Hermansky-Pudlak syndrome (PMID: 8896559, 20662851, 12442288, 9562579, 9497254) and has been identified in 0.03% (7/35412) of Latino/Admixed American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs281865163). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID#: 5277) and has been interpreted as Pathogenic by GeneReviews, Genetic Services Laboratory (University of Chicago), Clinical Molecular Genetics Laboratory (Johns Hopkins All Children's Hospital), Laboratory for Molecular Medicine (Partners HealthCare Personalized Medicine), Ambry Genetics, Invitae, EGL Genetic Diagnostics (Eurofins Clinical Diagnostics), GeneDx, OMIM, and Natera, Inc. In vitro functional studies provide some evidence that the p.His497fs variant may slightly impact protein function (PMID: 9345105). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 497 and leads to a premature termination codon 90 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the HPS1 gene is an established disease mechanism in autosomal recessive Hermansky-Pudlak syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Hermansky-Pudlak syndrome. ACMG/AMP Criteria applied: PM3, PS3_moderate, PVS1 (Richards 2015). |
Baylor Genetics | RCV000005595 | SCV004199912 | pathogenic | Hermansky-Pudlak syndrome 1 | 2024-03-28 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000482079 | SCV005413956 | pathogenic | not provided | 2024-08-13 | criteria provided, single submitter | clinical testing | PM3_strong, PS4_moderate, PVS1 |
OMIM | RCV000005595 | SCV000025777 | pathogenic | Hermansky-Pudlak syndrome 1 | 1998-04-30 | no assertion criteria provided | literature only | |
Gene |
RCV000005595 | SCV000054519 | not provided | Hermansky-Pudlak syndrome 1 | no assertion provided | literature only | ||
Natera, |
RCV000614559 | SCV001455561 | pathogenic | Hermansky-Pudlak syndrome | 2020-09-16 | no assertion criteria provided | clinical testing | |
Genomics And Bioinformatics Analysis Resource, |
RCV000005595 | SCV004024081 | pathogenic | Hermansky-Pudlak syndrome 1 | no assertion criteria provided | research | ||
Prevention |
RCV004754244 | SCV005346213 | pathogenic | HPS1-related disorder | 2024-03-21 | no assertion criteria provided | clinical testing | The HPS1 c.1472_1487dup16 variant is predicted to result in a frameshift and premature protein termination (p.His497Glnfs*90). This variant has been reported in individuals with Hermansky-Pudlak syndrome (Oh et al. 1996. PubMed ID: 8896559; Carmona-Rivera et al. 2011. PubMed ID: 20662851; Gahl et al. 1998. PubMed ID: 9562579). This variant is reported in 0.020% of alleles in individuals of Latino descent in gnomAD. Frameshift variants in HPS1 are expected to be pathogenic. This variant is interpreted as pathogenic. |